OliX Pharmaceuticals - About the company
OliX Pharmaceuticals is a public company based in Suwon-si (South Korea), founded in 2010 by Dong-ki Lee. It operates as a Developer of RNAi therapeutics for dermal, ophthalmic and pulmonary diseases.. OliX Pharmaceuticals has raised an undisclosed amount in funding. The company has 107 active competitors, including 36 funded and 32 that have exited. Its top competitors include companies like Alnylam, Nanopore Technologies and Sirnaomics.
Company Details
Developer of RNAi therapeutics for dermal, ophthalmic, and pulmonary diseases. Its drug pipeline includes OLX101 for the treatment of Skin Scar (licensed out to Huge Inc.), OLX201 for the treatment of Lung fibrosis, OLX301 for the treatment of Wet AMD/Retinal Fibrosis, OLX701 for liver fibrosis. Other products include OLX102 for skin whitening and OLX105 to get rid of wrinkles. The company's technology is based on three types of RNA: Small interfering RNA (siRNA), Asymmetric siRNA (siRNA), and Cell-penetrating asymmetric siRNA (cp-siRNA).
- Website
- olixpharma.com
- Social
- Email ID
- *****@olixpharma.com
- Phone Number
- +82 **********
- Registered Address
- 608-3 Godeung-dong, Sujeong-gu, Seongnam-si, Gyeonggi-do -
Key Metrics
Founded Year
2010
Location
Suwon-si, South Korea
Stage
Public
Latest Funding Round
Investors
Ranked
9th among 107 active competitors
Employee Count
62 as on Sep 30, 2026
Exit Details
Public
Legal entities associated with OliX Pharmaceuticals
OliX Pharmaceuticals is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Olix Co Ltd CIN: 124-86-90516 , South Korea, Active | Feb 26, 2010 | - | - | - |
OliX Pharmaceuticals's IPO details
OliX Pharmaceuticals got listed on Jul 20, 2018.
Click here to take a look at OliX Pharmaceuticals's IPO in detail
Sign up to download OliX Pharmaceuticals' company profile
OliX Pharmaceuticals's funding and investors
OliX Pharmaceuticals has raised funding over 1 round. Its latest funding round was a Post IPO round on Jun 02, 2026 for $*****. 2 investors participated in its latest round. OliX Pharmaceuticals has 18 institutional investors.
Here is the list of recent funding rounds of OliX Pharmaceuticals:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 02, 2026 | 6765938 | Post IPO | 2235925 | 7261649 | 8922038 | 2901190 |
Access funding benchmarks and valuations. Sign up today!View details of OliX Pharmaceuticals's funding rounds and investors
OliX Pharmaceuticals' founders and board of directors
Founder? Claim ProfileThe founders of OliX Pharmaceuticals is Dong-ki Lee.
Here are the details of OliX Pharmaceuticals' key team members:
- Dong-ki Lee: Founder & CEO of OliX Pharmaceuticals.
View details of OliX Pharmaceuticals's Founder profiles and Board Members
OliX Pharmaceuticals' employee count trend
OliX Pharmaceuticals has 62 employees as of Sep 26. Here is OliX Pharmaceuticals's employee count trend over the years:
Uncover OliX Pharmaceuticals' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
OliX Pharmaceuticals's Competitors and alternates
Top competitors of OliX Pharmaceuticals include Alnylam, Nanopore Technologies and Sirnaomics. Here is the list of Top 10 competitors of OliX Pharmaceuticals, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 79/100 | |
2nd | Nanopore Technologies 2005, Oxford (United Kingdom), Public | Manufacturer of portable and benchtop devices for real-time DNA sequencing | $1.34B | 75/100 | |
3rd | Sirnaomics 2007, Gaithersburg (United States), Public | Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease | $267M | 67/100 | |
4th |  Avidity Biosciences 2012, San Diego (United States), Acquired | RNA therapeutics innovator targeting muscle and other diseases with AOC platform | $143M | 66/100 | |
5th | Orna 2020, Cambridge (United States), Acquired | Developer of technologies for producing circular RNA therapeutics | $201M | 66/100 | |
6th | City Therapeutics 2006, Cambridge (United States), Series B | Developer of gene therapies for multiple diseases | $234M | 63/100 | |
7th | Rznomics 2017, Yongin si (South Korea), Public | Developer of drugs for anti-cancer and refractory diseases based on RNA Platform technology | $48.7M | 62/100 | |
8th | Arrowhead Pharmaceuticals 1989, Pasadena (United States), Acquired | Developer of therapeutics to treat multiple diseases | $60M | 62/100 | |
9th | OliX Pharmaceuticals 2010, Suwon-si (South Korea), Public | Developer of RNAi therapeutics for dermal, ophthalmic and pulmonary diseases. | - | 61/100 | |
10th | Dicerna Pharmaceuticals 2007, Lexington (United States), Acquired | Developer of drugs by using RNA interference technology platform | $106M | 60/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on OliX Pharmaceuticals's competitors? Click here to see the top ones
OliX Pharmaceuticals's Investments and acquisitions
OliX Pharmaceuticals has made no investments or acquisitions yet.
Reports related to OliX Pharmaceuticals
Here is the latest report on OliX Pharmaceuticals's sector:
News related to OliX Pharmaceuticals
Filter this listMedia has covered OliX Pharmaceuticals for a total of 3 events in the last 1 year, 1 of them has been about company updates and 1 about partnerships.
•
OliX Pharmaceuticals Secures KRW 110 Billion Investment from BOLD, L’Oréal Corporate Venture Capital Fund, and Weiss, U.S. Hedge FundBusiness Wire•Jun 04, 2026•Weiss Asset Management, BOLD, OliX Pharmaceuticals, Bold Capital Partners and 5 others
•
Vect-Horus and OliX Pharmaceuticals Partner on CNS-Focused siRNA Delivery ResearchGlobeNewswire•Feb 03, 2026•Vect-Horus, OliX Pharmaceuticals
•
AI Disclosure DB Director Kim Young-jin acquires 7,000 shares of Olix by exercising stock optionsDigitalToday•Aug 19, 2025•OliX Pharmaceuticals
•
OliX Receives European Patent for Hair Loss Treatment ‘OLX104C’Businesskorea•Jul 30, 2025•OliX Pharmaceuticals
•
Olix Signs Joint R&D Agreement with L’Oréal for Skin and Hair RegenerationBusinesskorea•Jun 09, 2025•OliX Pharmaceuticals, L'Oreal
•
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASHPharmaceutical Technology•Feb 11, 2025•Lilly, OliX Pharmaceuticals
•
OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic IndicationsBusiness Wire•Feb 10, 2025•OliX Pharmaceuticals, Lilly, China Eli Lilly and Company
•
Lilly inks agreement with South Korean RNAi developer for MASH assetSeeking Alpha•Feb 10, 2025•Lilly, OliX Pharmaceuticals
•
Is OliX Pharmaceuticals’ release of phase 2 results of OLX101A a half success?KBR•Apr 26, 2024•OliX Pharmaceuticals
•
OliX Pharmaceuticals Commences Patient Dosing in Phase 1 Clinical Trial of OLX75016 for MASHPipelinereview•Feb 14, 2024•OliX Pharmaceuticals
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about OliX Pharmaceuticals
Explore our recently published companies
- Hallway Talk - Denver based, 2014 founded, Unfunded company
- Shalom Hills - Gurugram based, 2004 founded, Unfunded company
- The Space Station - Unfunded company
- Ralph van Roosmalen - Unfunded company
- Universidad Virtual Hispanica de Mexico - Mexico based, Unfunded company
- BRANDOW'S FEED & SEED - Oneonta based, 2005 founded, Unfunded company
